Navigation Links
Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.  This trial, known as STEPWISE (a randomized, double-blind, multi-center STudy comparing cross-linkEd Polyelectrolyte (CLP) WIth placebo in HF SubjEcts), is designed to evaluate the safety and efficacy of CLP-1001 in addressing signs and symptoms of fluid overload in patients with congestive heart failure (HF).  CLP-1001 is a novel, non-absorbed oral polymer that acts by binding to and removing excess sodium and fluid in the GI tract independently of the kidneys.

"The objective of the STEPWISE trial is to further understand the magnitude of the effect of CLP-1001 on key measures and clinical endpoints of heart failure-induced congestion compared to current standard of care," said Howard C. Dittrich , M.D., F.A.C.C., Chief Medical Officer of Sorbent.  "Fluid overload in heart failure patients contributes importantly to hospitalizations -- including re-hospitalizations -- slows in-patient recovery, and results in poor quality of life and physical limitations.  Based on the positive clinical benefits observed in our Phase 2a clinical trial, we look forward to advancing CLP-1001 through late-stage registration studies."   

STEPWISE is a double-blind, randomized, placebo-controlled, multicenter, study designed to evaluate CLP-1001 in patients with heart failure.  Approximately 250 patients on stable, optimized, guideline heart failure therapy that have signs and symptoms of current fluid overload after a recent HF-related hospitalization will be randomized to receive 15 grams of CLP-1001 or placebo.  The primary objective of this trial is to assess the change from baseline to eight weeks across sever
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
3. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
4. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Australia, May 14 Progen,Pharmaceuticals Limited (ASX:PGL; Nasdaq: ... enrolment in the phase 1 dose-escalation study,of its ... with advanced cancer., Progen has commenced development ... Company,s polyamine program - following its acquisition of,Cellgate, ...
... for cervical cancer prevention, GRAZ, Austria, May ... show that GlaxoSmithKline (NYSE: GSK ) cervical,cancer ... antibodies against the two most common cervical cancer-causing,human ... is the longest,duration of sustained neutralizing antibody levels ...
Cached Medicine Technology:Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6
(Date:4/24/2014)... three survivors of critical illness, according to a ... Medicine , and the majority of patients experience ... is one of the largest studies to investigate ... care survivors, according to lead author James Jackson, ... a significant public health issue, with roughly 5 ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... 2014 Pregnant immigrants from Sub-Saharan Africa, Latin ... during pregnancy, according to new research from St. ... the British Journal of Obstetrics and Gynaecology ... rates among immigrants and native-born women in six ... Sweden, Spain (Catalonia and Valencia) and the United ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... not always connected, researchers say , , FRIDAY, May 2 ... disturbances experienced by Alzheimer,s disease patients and the sleep ... team from the University of Washington, in Seattle, found ... aren,t always connected. , The researchers studied 44 older ...
... Epidemiology Center have found that approximately one in ten ... medications during a given week. These findings will ... & Asian Society for Pediatric Research Joint Meeting in ... widely marketed in the U.S. but surprisingly little is ...
... following is,being issued today by SEIU -- Inter-Con ... unfair labor practice strike against,Inter-Con to defend their ... the,first-ever group of hospital security officers to strike. ... were trying to form a,union for better conditions., ...
... Australian researchers have unveiled a new immunotherapy technique ... to AIDS. Details of the simple, cost-effective ... journal PLoS Pathogens. , There is an overwhelming ... therapies are expensive, impractical, and often highly toxic. ...
... WARSAW, Ind., May 2 Zimmer Holdings, Inc.,(NYSE ZMH; ... the,Deutsche Bank Securities 33rd Annual Health Care Conference, in ... Time., A live webcast of the presentation can ... . The webcast will,be archived for replay following ...
... says , , FRIDAY, May 2 (HealthDay News) -- Heart failure ... cancer, a new study finds. , Indeed, people in the ... inability to supply the body with oxygen-carrying blood, had measures ... that are seen in people with advanced cancer, Dr. David ...
Cached Medicine News:Health News:Sleep Troubles Vary Between Alzheimer's Patients, Caregivers 2Health News:1 in 10 children using cough, cold medications 2Health News:First-Ever Group of Hospital Security Officers to Strike over Unfair Labor Practices, Walk out of Facilities Across California on May 6 2Health News:Suffering of Heart Failure Similar to Cancer 2Health News:Suffering of Heart Failure Similar to Cancer 3
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
... & Solutions offers a wide variety ... needs of healthcare professionals. Whether you ... prefer a dry scrub brush in ... brushes provide the flexibility and options ...
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
Medicine Products: